Juventas Cell Therapy closes a $63M funding round as it eyes a big push for blood cancer hopeful

Juventas has grabbed a $63 million series C to advance its CASI Pharmaceuticals-partnered drug CNCT19.

The new swag will be used toward an NDA for the cell therapy as it eyes a future sales plan for the drug.

CASI, which said it welcomed the fundraise, currently shares global co-commercial and profit-sharing rights with Juventas and indirectly owns a 12% equity stake in Juventas. The biotech’s latest raise was led by CICC Capital.